3 results
Not approvedWill not start
The primary objective of this study is to evaluate the proportion of patients achieving FXI inhibition * 80% at trough (Day 91) after monthly dosing at 3 dose levels of MAA868.
Approved WMOPending
To assess the diagnostic performance of PCCT to identify the luminal patency compared with ICA as the reference standard, in patients with a history of PCI with stent placement and to assess image quality by applying different image reconstruction…
Approved WMOCompleted
To assess the efficacy of GV-971 compared with placebo on cognition and global function in participants with mild to moderate Alzheimer's disease (AD).